Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advancing targeted protein degradation for metabolic diseases therapy
Qianqian Zhou, Haitao Xiao, Fan Yang, et al.
Pharmacological Research (2022) Vol. 188, pp. 106627-106627
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Nano-PROTACs: state of the art and perspectives
Jie Zhong, Ruiqi Zhao, Yuji Wang, et al.
Nanoscale (2024) Vol. 16, Iss. 9, pp. 4378-4391
Closed Access | Times Cited: 19
Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders
Samradhi Singh, Devojit Kumar Sarma, Vinod Verma, et al.
Biochemical and Biophysical Research Communications (2023) Vol. 682, pp. 1-20
Closed Access | Times Cited: 40
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice
Xiaoding Ma, Jianli Yin, Longliang Qiao, et al.
Molecular Cell (2024) Vol. 84, Iss. 8, pp. 1585-1600.e7
Closed Access | Times Cited: 9
Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum
Juhyeong Hong, Yong‐Hee Kim
Journal of Controlled Release (2025) Vol. 380, pp. 433-456
Closed Access | Times Cited: 1
New strategies to enhance the efficiency and precision of drug discovery
Qi An, Liang Huang, Chuan Wang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Targeted protein degradation in drug development: Recent advances and future challenges
Jian H. Song, Mingzheng Hu, Jun Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115839-115839
Closed Access | Times Cited: 18
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, et al.
Cells (2024) Vol. 13, Iss. 7, pp. 578-578
Open Access | Times Cited: 7
Targeted Protein Degradation: Principles and Applications of the Proteasome
Yosup Kim, Eun-Kyung Kim, Yoona Chey, et al.
Cells (2023) Vol. 12, Iss. 14, pp. 1846-1846
Open Access | Times Cited: 13
Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
Design, synthesis and cytotoxic activity of molecular hybrids based on quinolin-8-yloxy and cinnamide hybrids and their apoptosis inducing property
Dalal Nasser Binjawhar, Fawziah A. Al‐Salmi, Ola A. Abu Ali, et al.
RSC Advances (2024) Vol. 14, Iss. 16, pp. 11443-11451
Open Access | Times Cited: 5
Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review
Mary Sravani Galla, Nitika Sharma, Priyanka Mishra, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 8, pp. 2585-2600
Closed Access | Times Cited: 5
Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases
Yelin Jeong, Ah‐Reum Oh, Young Hoon Jung, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 10, pp. 2097-2104
Open Access | Times Cited: 12
Beyond Tumors: The Pivotal Role of TRIM Proteins in Chronic Non-Tumor Lung Diseases
Xiangfei Huang, Wen Yu, Anhua Wei, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 1899-1910
Open Access
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, et al.
Chinese Journal of Natural Medicines (2025) Vol. 23, Iss. 3, pp. 286-298
Closed Access
Interplay of PROTAC Complex Dynamics for Undruggable Targets: Insights into Ternary Complex Behavior and Linker Design
Harish Kumar, M. Elizabeth Sobhia
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 8, pp. 1306-1318
Closed Access | Times Cited: 3
Facilitating the development of molecular glues: Opportunities from serendipity and rational design
Weiqing Jiang, Yunhan Jiang, Youfu Luo, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115950-115950
Closed Access | Times Cited: 8
Targeted degradation of hexokinase 2 for anti‑inflammatory treatment in acute lung injury
Jiayan Yang, Liangliang Dong, Yifan Wang, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 5
Open Access | Times Cited: 2
Novel Functional Food Properties of Forest Onion (Eleutherine bulbosa Merr.) Phytochemicals for Treating Metabolic Syndrome: New Insights from a Combined Computational and In Vitro Approach
Happy Kurnia Permatasari, Nuril Farid Abshori, Rony Abdi Syahputra, et al.
Nutrients (2024) Vol. 16, Iss. 10, pp. 1441-1441
Open Access | Times Cited: 2
Lysosome and related protein degradation technologies
Hongmei Zheng, Gangjian Li, Jingli Min, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103767-103767
Closed Access | Times Cited: 4
Lysosome-targeting solid state NIR emissive donor–acceptor molecules: a study on photophysical modulation through architectural distinction
Ashish Kumar Kushwaha, Ankit Kumar Srivastava, Pradeep Kumar, et al.
New Journal of Chemistry (2024) Vol. 48, Iss. 13, pp. 5589-5598
Closed Access | Times Cited: 1
GSK3β and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer
Wulin Shan, Wenju Peng, Yao Chen, et al.
Oncogene (2024) Vol. 43, Iss. 25, pp. 1885-1899
Closed Access | Times Cited: 1
Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117584-117584
Open Access | Times Cited: 1
PROTAC-mediated FTO protein degradation effectively alleviates diet-induced obesity and hepatic steatosis
Yang Xiao, Tianyu Jiang, Xinyi Qi, et al.
International Journal of Biological Macromolecules (2024) Vol. 285, pp. 138292-138292
Closed Access | Times Cited: 1
CRBN ligand expansion for hematopoietic prostaglandin D2 synthase (H-PGDS) targeting PROTAC design and their in vitro ADME profiles
Hinata Osawa, Takashi Kurohara, Takahito Ito, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 84, pp. 117259-117259
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top